These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2521808)

  • 1. The effects of thionapthene-2-carboxylic acid-lysine on the hypercalcemia of malignancy in the rat.
    Decker JE; Morrison NE; Lorenzo JA; Samour CM; McCarron BA; Raisz LG
    Calcif Tissue Int; 1989 Jan; 44(1):61-4. PubMed ID: 2521808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thionapthene-2-carboxylic acid: a new antihypercalcemic agent.
    Johannesson AJ; Onkelinx C; Rodan GA; Raisz LG
    Endocrinology; 1985 Oct; 117(4):1508-11. PubMed ID: 4029089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor.
    Martodam RR; Thornton KS; Sica DA; D'Souza SM; Flora L; Mundy GR
    Calcif Tissue Int; 1983 Jul; 35(4-5):512-9. PubMed ID: 6311375
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal phosphate transport in humoral hypercalcemia of malignancy.
    Sartori L; Insogna KL; Barrett PQ
    Am J Physiol; 1988 Dec; 255(6 Pt 2):F1078-84. PubMed ID: 2974244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
    Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
    Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
    Brown GM; Morris CA; Mitnick MA; Insogna KL
    J Bone Miner Res; 1990 Oct; 5(10):1037-41. PubMed ID: 1964358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
    Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
    Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
    Hirschel-Scholz S; Caverzasio J; Rizzoli R; Bonjour JP
    J Clin Invest; 1986 Jul; 78(1):319-22. PubMed ID: 3013941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral hypercalcemia caused by a rat Leydig-cell tumor is associated with suppressed parathyroid hormone secretion and increased urinary cAMP excretion.
    Spiegel AM; Saxe AW; Deftos LJ; Brennan MF
    Horm Metab Res; 1983 Jun; 15(6):299-304. PubMed ID: 6307850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parenteral diphosphonates for treating malignant hypercalcemia.
    Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
    Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice H-500 Leydig cell or C26-DCT colon tumors.
    Colloton M; Shatzen E; Wiemann B; Starnes C; Scully S; Henley C; Martin D
    Eur J Pharmacol; 2013 Jul; 712(1-3):8-15. PubMed ID: 23623934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
    Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
    J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy.
    Insogna KL; Stewart AF; Vignery AM; Weir EC; Namnum PA; Baron RE; Kirkwood JM; Deftos LM; Broadus AE
    Endocrinology; 1984 Mar; 114(3):888-96. PubMed ID: 6546543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hypercalcemic rat Leydig cell tumor--a model of the humoral hypercalcemia of malignancy.
    Sica DA; Martodam RR; Aronow J; Mundy GR
    Calcif Tissue Int; 1983 May; 35(3):287-93. PubMed ID: 6871760
    [No Abstract]   [Full Text] [Related]  

  • 15. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
    Haq M; Kremer R; Goltzman D; Rabbani SA
    J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of low calcium diet, mithramycin, and dichlorodimethylene bisphosphonate on humoral hypercalcemia of malignancy in nude mice transplanted with the canine adenocarcinoma tumor line (CAC-8).
    Rosol TJ; Capen CC
    J Bone Miner Res; 1987 Oct; 2(5):395-405. PubMed ID: 2971305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clodronate treatment in patients with malignancy-associated hypercalcemia.
    Rastad J; Benson L; Johansson H; Knuutila M; Pettersson B; Wallfelt C; Akerström G; Ljunghall S
    Acta Med Scand; 1987; 221(5):489-94. PubMed ID: 2955674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of passive immunization against parathyroid hormone (PTH)-like peptide and PTH in hypercalcemic tumor-bearing rats and normocalcemic controls.
    Henderson J; Bernier S; D'Amour P; Goltzman D
    Endocrinology; 1990 Sep; 127(3):1310-8. PubMed ID: 2167215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dichloromethylene diphosphonate action in hematologic and other malignancies.
    Canfield RE; Siris ES; Jacobs TP
    Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased production of tumor necrosis factor by normal immune cells in a model of the humoral hypercalcemia of malignancy.
    Sabatini M; Yates AJ; Garrett IR; Chavez J; Dunn JF; Bonewald L; Mundy GR
    Lab Invest; 1990 Nov; 63(5):676-82. PubMed ID: 2232714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.